Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Article
en En
| MEDLINE
| ID: mdl-25892145
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Quinazolinas
/
Carcinoma de Células Escamosas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Metotrexato
/
Neoplasias de Cabeza y Cuello
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Lancet Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2015
Tipo del documento:
Article